Broadband Cortical Desynchronization Underlies Psychedelic State

Broadband Cortical Desynchronization Underlies the Human Psychedelic State   Psychedelic drugs produce profound changes in consciousness, but the underlying neurobiological mechanisms for this remain unclear. Spontaneous and induced oscillatory activity was recorded in healthy human participants with magnetoencephalography after intravenous infusion of psilocybin—prodrug of the nonselective serotonin 2A receptor agonist and classic psychedelic psilocin. Psilocybin …

Read moreBroadband Cortical Desynchronization Underlies Psychedelic State

LSD enhances the emotional response to music

Rationale There is renewed interest in the therapeutic potential of psychedelic drugs such as lysergic acid diethylamide LSD). LSD was used extensively in the 1950s and 1960s as an adjunct in psychotherapy, reportedly enhancing emotionality. Music is an effective tool to evoke and study emotion and is considered an important element in psychedelic-assisted psychotherapy; however, …

Read moreLSD enhances the emotional response to music

Implications for psychedelic assisted psychotherapy

magnetic resonance imaging study with psilocybin – Implications for psychedelic-assisted psychotherapy: functional Background Psilocybin is a classic psychedelic drug that has a history of use in psychotherapy. One of the rationales for its use was that it aids emotional insight by lowering psychological defences. Aims To test the hypothesis that psilocybin facilitates access to personal …

Read moreImplications for psychedelic assisted psychotherapy

Psychedelic drugs should be legally reclassified

Psychedelic drugs should be legally reclassified so that researchers can investigate their therapeutic potential Trials of physiologically safe and non-addictive drugs such as LSD are almost impossible, writes James J H Rucker, calling on the authorities to downgrade their unnecessarily restrictive class A, schedule 1 classification James J H Rucker specialist registrar in adult psychiatry …

Read morePsychedelic drugs should be legally reclassified

Finding the Self by Losing the Self

Finding the Self by Losing the Self: Neural Correlates of Ego-Dissolution Under Psilocybin Ego-disturbances have been a topic in schizophrenia research since the earliest clinical descriptions of the disorder. Manifesting as a feeling that one’s “self,” “ego,” or “I” is disintegrating or that the border between one’s self and the external world is dissolving, “ego-disintegration” …

Read moreFinding the Self by Losing the Self

Psychedelic drugs should be legally reclassified so that researchers can investigate their therapeutic potential

Trials of physiologically safe and non-addictive drugs such as LSD are almost impossible, writes James J H Rucker, calling on the authorities to downgrade their unnecessarily restrictive class A, schedule 1 classification

Psychedelic drugs, especially lysergic acid diethylamide (LSD) and psilocybin, which is found in the Psilocybe genus of “magic” mushrooms that grow throughout the United Kingdom, were extensively used and researched in clinical psychiatry before their prohibition in 1967. Hundreds of papers, involving tens of thousands of patients, presented evidence for their use as psychotherapeutic catalysts of mentally beneficial change in many psychiatric disorders, problems of personality development, recidivistic behaviour, and existential anxiety.1

This research abruptly ended after 1967, when psychedelics were legally classified as schedule 1 drugs under the UK Misuse of Drugs Regulations and as class A drugs under the UK Misuse of Drugs Act 1971. Schedule 1 in the UK broadly mirrors schedule I of the 1971 United Nations Convention on Psychotropic Substances, adoption of which is a requirement of UN membership.2 This classification denoted psychedelic drugs as having no accepted medical use and the greatest potential for harm, despite the existence of research evidence to the contrary.

Indeed, in 1992 John Ehrlichman, …

Psychedelic drugs should be legally reclassified so that researchers can investigate their therapeutic potential | The BMJ.

  1. James J H Rucker, specialist registrar in adult psychiatry and honorary clinical lecturer, MRC Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King’s College, London, SE5 8AF
  1. james.rucker{at}kcl.ac.uk